Armin Walser Phones & Addresses
-
5900 Camino Miraval, Tucson, AZ 85718 (520) 299-3274
-
West Caldwell, NJ
Work
Position:
Professional/Technical
Education
Degree:
Graduate or professional degree
Publications
Us Patents
Substituted Benzimidazoles
View pageUS Patent:
6358978, Mar 19, 2002
Filed:
Jun 22, 2000
Appl. No.:
09/599390
Inventors:
Olaf Ritzeler - Frankfurt am Main, DE
Hans Ulrich Stilz - Frankfurt, DE
Bernhard Neises - Offenburg, DE
Armin Walser - Tucson AZ
Gary A. Flynn - Tucson AZ
Jörg Habermann - Bad Soden, DE
Gerhard Jähne - Frankurt am Main, DE
Hans Ulrich Stilz - Frankfurt, DE
Bernhard Neises - Offenburg, DE
Armin Walser - Tucson AZ
Gary A. Flynn - Tucson AZ
Jörg Habermann - Bad Soden, DE
Gerhard Jähne - Frankurt am Main, DE
Assignee:
Aventis Pharma Deutschland GmbH - Frankfurt
International Classification:
A61K 31445
US Classification:
514319, 51421108, 51421115, 51421703, 51422708, 5142335, 51425206, 51425406, 514256, 514314, 514394, 540553, 540603, 544 60, 544132, 544238, 544333, 544366, 546199, 546152, 5483047
Abstract:
Compounds of formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF B is involved.
Malonic Acid Derivatives, Processes For Their Preparation, For Their Use And Pharmaceutical Compositions Containing Them
View pageUS Patent:
6395737, May 28, 2002
Filed:
Dec 28, 1999
Appl. No.:
09/473053
Inventors:
Elisabeth Defossa - Idstein, DE
Uwe Heinelt - Wiesbaden, DE
Otmar Klingler - Rodgau, DE
Gerhard Zoller - Schöneck, DE
Hans Matter - Langenselbold, DE
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
Peter Wildgoose - Oberursel, DE
Uwe Heinelt - Wiesbaden, DE
Otmar Klingler - Rodgau, DE
Gerhard Zoller - Schöneck, DE
Hans Matter - Langenselbold, DE
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
Peter Wildgoose - Oberursel, DE
Assignee:
Aventis Pharma Deutschland GmbH - Frankfurt am Main
International Classification:
A61K 31165
US Classification:
51425212, 51425501, 514329, 514331, 514423, 514522, 514539, 514563, 514604, 514616, 544383, 544389, 544391, 544400, 546224, 546331, 548540, 558414, 560 35, 560 41, 562440, 562450, 564 91, 564153
Abstract:
New compounds for the inhibition of blood clotting proteins, and more particularly, to malonic acid derivatives of the formula I, wherein R(1), R(2), R(3), R(4), R(5), and R(6) have the meanings indicated in the claims. The compounds of formula I are inhibitors of the blood clotting enzyme factor Xa. Processes for the preparation of the compounds of formula I, methods of inhibiting factor Xa activity and of inhibiting blood clotting, use of the compounds of formula I in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, and use of the compounds of formula I in the preparation of medicaments to be applied in such diseases. Compositions containing a compound of formula I in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula I together with pharmaceutically acceptable carrier substances and auxiliary substances.
N-Guanidinoalkylamides, Their Preparation, Their Use, And Pharmaceutical Preparations Comprising Them
View pageUS Patent:
6472562, Oct 29, 2002
Filed:
Oct 27, 2000
Appl. No.:
09/697188
Inventors:
Otmar Klingler - Rodgau, DE
Gerhard Zoller - Schöneck, DE
Elisabeth Defossa - Idstein, DE
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
James Ostrem - Tucson AZ
Gerhard Zoller - Schöneck, DE
Elisabeth Defossa - Idstein, DE
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
James Ostrem - Tucson AZ
Assignee:
Aventis Pharma Deutschland GmbH - Frankfurt
International Classification:
C07C23305
US Classification:
564157, 514357, 514565, 514616, 546332, 562439, 564153
Abstract:
The present invention relates to compounds of the formula I, in which A, L, Y, and k have the meanings indicated in the specification and claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa and/or factor VIIa and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of conditions in which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
N-Guanidinoalkylamides, Their Preparation, Their Use, And Pharmaceutical Preparations Comprising Them
View pageUS Patent:
6664393, Dec 16, 2003
Filed:
Aug 26, 2002
Appl. No.:
10/227222
Inventors:
Otmar Klingler - Rodgau, DE
Gerhard Zoller - Schöneck, DE
Elisabeth Defossa - Idstein, DE
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
James Ostrem - Tucson AZ
Gerhard Zoller - Schöneck, DE
Elisabeth Defossa - Idstein, DE
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
James Ostrem - Tucson AZ
Assignee:
Aventis Pharma Deutschland GmbH - Frankfurt am Main
International Classification:
C07D23924
US Classification:
544301, 514269, 514307, 514309, 514312, 514357, 546141, 546146, 546156, 546332, 546329, 546335
Abstract:
The present invention relates to compounds of the formula I, in which A, L, Y, and k have the meanings indicated in the specification and claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa and/or factor VIIa and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of conditions in which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
Factor Xa Inhibitors
View pageUS Patent:
6759384, Jul 6, 2004
Filed:
Dec 14, 1998
Appl. No.:
09/211715
Inventors:
Fahad Al-Obeidi - Tucson AZ
Michal Lebl - Tucson AZ
James A. Ostrem - Tucson AZ
Pavel Safar - Tucson AZ
Peter Strop - Tucson AZ
Armin Walser - Tucson AZ
Michal Lebl - Tucson AZ
James A. Ostrem - Tucson AZ
Pavel Safar - Tucson AZ
Peter Strop - Tucson AZ
Armin Walser - Tucson AZ
Assignee:
Aventis Pharmaceuticals Inc. - Bridgewater NJ
International Classification:
A61K 3855
US Classification:
514 2, 530384, 530381, 530380, 530420
Abstract:
The invention provides compounds which specifically inhibit factor Xa activity having the structure A âA â(A ) âB, where m is 0 or 1. A compound of the invention is characterized, in part, in that it exhibits a specific inhibition of factor Xa activity with a K 100 M, preferably 2 nM, and does not substantially inhibit the activity of other proteases involved in the coagulation cascade. The invention further provides methods of specifically inhibiting the activity of factor Xa and of inhibiting blood clotting in vitro and in an individual and methods of detecting factor Xa levels or activity.
Arylalkanoyl Derivatives, Processes For Their Preparation, Their Use And Pharmaceutical Compositions Containing Them
View pageUS Patent:
6759420, Jul 6, 2004
Filed:
Dec 28, 1999
Appl. No.:
09/472936
Inventors:
Elisabeth Defossa - Idstein, DE
Uwe Heinelt - Wiesbaden, DE
Otmar Klingler - Rodgau, DE
Gerhard Zoller - Schöneck, DE
Hans Matter - Langenselbold, DE
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
Peter Wildgoose - Oberursel, DE
Uwe Heinelt - Wiesbaden, DE
Otmar Klingler - Rodgau, DE
Gerhard Zoller - Schöneck, DE
Hans Matter - Langenselbold, DE
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
Peter Wildgoose - Oberursel, DE
Assignee:
Aventis Pharma Deutschland GmbH - Frankfurt am Main
International Classification:
A61K 3134
US Classification:
514337, 546224
Abstract:
The present invention is directed to new compounds for the inhibition of blood clotting proteins and factor Xa activity, and more particularly, to arylalkanoyl derivatives of the formula (I): wherein R(1), R(2), R(3), R(4), R(5), R(6 ), and R(6 ) have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (I), to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula (I) in the treatment and prophylaxis of diseases whcih can be treated or prevented by the inhibition of factor Xa activity, such as cardiovascular or thromboembolic diseases, and to the use of the compounds of formula (I) in the preparation of medicaments to be applied in such diseases.
Substituted Amides, Sulfonamides And Ureas Useful For Inhibiting Kinase Activity
View pageUS Patent:
6777577, Aug 17, 2004
Filed:
Jul 9, 2002
Appl. No.:
10/191718
Inventors:
Pavel Safar - Tuscon AZ
Armin Walser - Tuscon AZ
Stephen James Shimshock - Hillsborough NJ
Armin Walser - Tuscon AZ
Stephen James Shimshock - Hillsborough NJ
Assignee:
Aventis Pharmaceuticals Inc. - Bridgewater NJ
International Classification:
C07C23305
US Classification:
564153, 548491, 514415, 514419, 514616
Abstract:
Amide, sulfonamide and urea compounds having an inhibitory effect on Src kinase including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formulae I and II:.
Malonic Acid Derivatives, Processes For Their Preparation Their Use And Pharmaceutical Compositions Containing Them
View pageUS Patent:
6794365, Sep 21, 2004
Filed:
Feb 23, 2001
Appl. No.:
09/790641
Inventors:
Fahad A. Al-Obeidi - Tucson AZ
Armin Walser - Tucson AZ
Peter Wildgoose - Oberursel, DE
Armin Walser - Tucson AZ
Peter Wildgoose - Oberursel, DE
Assignee:
Aventis Pharma Deutschland GmbH - Frankfurt am Main
International Classification:
C07K 506
US Classification:
514 19, 514 18, 530331, 530332
Abstract:
The present invention relates to new malonic acid derivatives of the formula I, wherein R(1), R(2), R(3), R(4), R(5), and R(6) have the meanings indicated in the claims. The compounds of formula I are inhibitors of the blood clotting enzyme factor Xa. The invention also relates to processes for the preparation of the compounds of formula I, to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula I in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, and to the use of the compounds of formula I in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula I in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula I together with pharmaceutically acceptable carrier substances and auxiliary substances.